GENEVA (AP) — Swiss drug maker Roche Holding AG has ended development of a cholesterol drug that it had hoped could achieve blockbuster status.
Basel-based Roche announced Monday it is pulling the plug on dalcetrapib, which was in late-stage trials to study if it could increase so-called "good" cholesterol.
The company said in a statement the decision was based on the recommendation of its independent data and safety monitoring board.
Recommended For You
Dr. Hal Barron, chief medical officer and head of global product development, said the drug maker was "disappointed by the fact that this drug didn't provide benefit to the patients in our study."
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
